Seno

Opto-acoustic imaging technology combines optics and acoustics with a goal of improving the accuracy of the cancer diagnosis without the use of ionizing radiation (x-ray). The process starts by illuminating the breast with laser light of specific wavelengths. Tumors preferentially absorb the light over normal tissue and become slightly heated. A transient thermoelastic expansion causes a tumor to emit a pressure (acoustic) wave. This acoustic wave is then detected by an array of sensors positioned around the periphery of the breast held within the probe.

Research Imaging

Seno Medical’s first commercial product is a functional imaging device to address unmet needs of cancer researchers in small animal imaging. This device, which does not require FDA approval and will not be used for patient diagnosis has been licensed to a world market leader, VisualSonics of Toronto Canada.

American Cancer Society statistics indicate that early-stage breast cancer detection and follow-up offers a 96% to 98% chance of survival whereas less than a 52% survival rate is predicted for cancer detected at Stage 3 or 4. The potential for detecting smaller tumors holds great promise for significantly improving breast cancer diagnosis and treatment.